Aardvark Therapeutics, Inc. (AARD): who owns it and who trades it
As of Nov 16, 2026, AARD insiders reported 2 open-market sales worth $395K and 2 purchases worth $145K in the last 12 months, with 0% of the sale value made under pre-set 10b5-1 plans. The largest seller was Nelson Sun (See Remarks), with $395K. 3 of the 50 famous funds we follow held it at their last quarter end.
Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.
At a glance
Who is buying and selling Aardvark Therapeutics
From the latest filingsOverall: about as much buying as selling. Famous investors mostly sold. Funds and insiders were close to even.
Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.
Who owns AARD
72 funds and institutions reported AARD shares worth $55M at the end of Q2 2026, about 44% of the company. The largest holder is Decheng Capital LLC with 18.0%.
Funds and institutions (13F) 44%Everyone else 56%
10 largest owners, by share of the company
Top 20 owners
| Owner | Shares | % of company | Value | Change since Q1 2026 |
|---|---|---|---|---|
| Decheng Capital LLC | 3.92M | 17.96% | $22.6M | No change |
| Citadel Advisors LLC | 1.28M | 5.88% | $7.4M | +3% |
| Laurion Capital Management LP | 1.03M | 4.74% | $6M | No change |
| Vanguard Capital Management LLC | 562,877 | 2.58% | $3.2M | +2% |
| AQR Capital Management LLC | 480,249 | 2.20% | $2.8M | +257% |
| EcoR1 Capital, LLC | 396,194 | 1.82% | $2.3M | New |
| Adage Capital Partners Gp, L.l.c. | 300,000 | 1.38% | $1.7M | No change |
| Cantor Fitzgerald, L. P. | 233,164 | 1.07% | $1.3M | +250% |
| BlackRock, Inc. | 187,045 | 0.86% | $1.1M | -76% |
| Geode Capital Management, LLC | 149,844 | 0.69% | $864K | -52% |
| Two Sigma Investments, LP | 108,377 | 0.50% | $624K | -34% |
| Raymond James Financial Inc | 79,284 | 0.36% | $457K | +628% |
| Vanguard Fiduciary Trust Co | 75,172 | 0.34% | $433K | -10% |
| Woodline Partners LP | 72,429 | 0.33% | $417K | No change |
| Millennium Management LLC | 69,948 | 0.32% | $403K | -29% |
| State Street Corp | 59,273 | 0.27% | $341K | -70% |
| J. Goldman & Co LP | 40,500 | 0.19% | $233K | New |
| Ieq Capital, LLC | 38,382 | 0.18% | $221K | +133% |
| UBS Group AG | 35,639 | 0.16% | $205K | -77% |
| Morgan Stanley | 30,177 | 0.14% | $174K | +72% |
From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.
Insider trades
In the last 12 months, AARD insiders reported $145K of open-market purchases and $395K of sales. 0% of the sale value was under a 10b5-1 plan, a schedule set up in advance.
Purchases and sales by month
Latest trades
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Sep 11, 2026 | Nelson Sun | See Remarks | Sale | 62,000 | $5.18 | $321K | Form 4 |
| Sep 10, 2026 | Nelson Sun | See Remarks | Sale | 14,754 | $5.00 | $73.8K | Form 4 |
| Dec 11, 2025 | Nelson Sun | CFO | Purchase | 3,000 | $14.40 | $43.2K | Form 4 |
| Dec 11, 2025 | Tien-Li Lee | CEO | Purchase | 7,000 | $14.49 | $101K | Form 4 |
Insiders by value traded
| Insider | Role | Bought | Sold | Last trade |
|---|---|---|---|---|
| Nelson Sun | Chief Financial Officer | $43.2K | $395K | Sep 11, 2026 |
| Tien-Li Lee | Chief Executive Officer, Director, 10% owner | $101K | – | Dec 11, 2025 |
What this data shows, and what it doesn't
- Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
- Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
- "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
- Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
- Filings are self-reported and can be amended. Each trade links to its original filing. Methodology
AARD short interest
Low short interest. 4.7% of AARD shares are sold short: about 1 share in 21. Over the last 12 reports the number of shares short went up 2%.
As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.
As of Oct 30, 2026, 1.04M AARD shares were sold short, 4.7% of the shares outstanding, up 87.8% from the report before. At the average daily volume of 2.76M shares, buying them all back would take about 1.0 trading days (days to cover).
Shares short, % of all shares
Days to cover
Every report
| Settlement date | Shares short | % of shares | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|---|
| Oct 30, 2026 | 1.04M | 4.75% | +88% | 2.76M | 1.0 |
| Oct 15, 2026 | 553,262 | 2.53% | +17% | 152,381 | 3.6 |
| Sep 30, 2026 | 474,080 | 2.17% | +12% | 89,631 | 5.3 |
| Sep 15, 2026 | 424,912 | 1.94% | -17% | 149,572 | 2.8 |
| Aug 31, 2026 | 509,891 | 2.33% | -17% | 135,107 | 3.8 |
| Aug 14, 2026 | 611,764 | 2.80% | -6% | 116,588 | 5.2 |
| Jul 31, 2026 | 652,496 | 2.98% | +0% | 145,359 | 4.5 |
| Jul 15, 2026 | 651,789 | 2.99% | +23% | 675,701 | 1.0 |
| Jun 30, 2026 | 528,265 | 2.42% | -42% | 312,175 | 1.7 |
| Jun 15, 2026 | 911,832 | 4.18% | -8% | 131,002 | 7.0 |
| May 29, 2026 | 987,661 | 4.53% | -3% | 178,109 | 5.5 |
| May 15, 2026 | 1.01M | 4.65% | -20% | 183,666 | 5.5 |
Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks
Aardvark Therapeutics company events
Aardvark Therapeutics filed 15 reports on Form 8-K in the last 12 months, 3 of them about an important change (leadership). The latest was on Oct 23, 2026.
- Oct 23, 2026AnnouncementAardvark Therapeutics, Inc. issued a press release reporting exploratory efficacy data from its previously terminated Phase 3 Hunger Elimination or Reduction Objective trial and open-label extension trial. Filing
- Oct 22, 2026AnnouncementAardvark Therapeutics, Inc. issued a press release announcing that the U.S. Food and Drug Administration lifted the clinical hold on the Company’s Investigational New Drug application for ARD-101 for the treatment of hyperphagia in Prader-Willi Syndrome and announcing the Company will host a live… Filing
- Oct 8, 2026LeadershipThe board of directors of Aardvark Therapeutics, Inc. appointed David (Zhongwei) Zhang, Ph.D., MBA, as a Class II director of the Company, effective October 7, 2026. Filing
- Aug 17, 2026VoteReported shareholder vote results. Filing
- Aug 11, 2026ResultsReleased financial results. Filing
- Jun 12, 2026LeadershipAardvark Therapeutics, Inc. entered into a retention bonus letter agreement with Nelson Sun, the Company’s Chief Financial Officer and Chief Operating Officer. Filing
- May 14, 2026AnnouncementAardvark Therapeutics, Inc. issued a press release announcing that the U.S. Food and Drug Administration has placed a full clinical hold on its investigational new drug application for ARD-101. Filing
- May 7, 2026ResultsReleased financial results. Filing
- Mar 24, 2026AgreementAardvark Therapeutics, Inc. entered into an Equity Distribution Agreement with Piper Sandler & Co., as sales agent, pursuant to which the Company may, from time to time, in its sole discretion, offer and sell through or to the Agent, shares of its common stock, par value $0.00001 per share. Filing
- Mar 23, 2026ResultsReleased financial results. Filing
- Feb 27, 2026AnnouncementAardvark Therapeutics, Inc. issued a press release announcing that the Company is voluntarily pausing its Phase 3 Hunger Elimination or Reduction Objective (HERO) trial, which is a Phase 3 randomized, double-blind, placebo-controlled trial evaluating the efficacy and safety of ARD-101 as a… Filing
- Feb 12, 2026LeadershipBryan Jones, Ph.D., the current Chief Operating Officer of Aardvark Therapeutics, Inc. commenced serving as the Chief Executive Officer of Ardia Therapeutics, Inc., a wholly-owned subsidiary of the Company and, in connection therewith, effective February 9, 2026, Dr. Jones ceased serving as the… Filing
- Feb 10, 2026AnnouncementAardvark Therapeutics, Inc. issued a press release announcing that Institutional Review Board approval has been granted in the United States for an amended protocol to its ongoing Phase 3 HERO pivotal clinical trial evaluating ARD-101 for the treatment of hyperphagia in individuals with… Filing
- Jan 12, 2026AnnouncementAardvark Therapeutics, Inc. updated its corporate presentation for use in meetings from time to time with investors, analysts and others, which corporate presentation will also be posted to the Company’s website. Filing
- Dec 10, 2025AnnouncementAardvark Therapeutics, Inc. issued a press release announcing that the first patient has been dosed in Australia in the Company's Phase 3 HERO pivotal clinical trial assessing ARD-101 for the treatment of hyperphagia in individuals with Prader-Willi syndrome. Filing
From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week
Aardvark Therapeutics financials
Famous investors that hold AARD
3 of the 50 well-known investors we track reported holding AARD in their latest 13F filing. The largest position is Ken Griffin's, worth $5.1M.
Position size
All holders
| Fund | Quarter | Shares | Value | Of portfolio | Change |
|---|---|---|---|---|---|
| Ken Griffin · Citadel Advisors | Q3 2026 | 975,028 | $5.1M | 0.0% | -24% |
| Israel Englander · Millennium Management | Q3 2026 | 62,454 | $329K | 0.0% | -11% |
| Steve Cohen · Point72 Asset Management | Q3 2026 | 35,456 | $187K | 0.0% | +55% |
From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.
5%+ stakes filed in the last 120 days
Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 2 filings named AARD in the last 120 days.
| Filed | Holder | Form | Stake |
|---|---|---|---|
| Nov 16, 2026 | Citadel Advisors LLC | 13G/A | 4.3% |
| Nov 16, 2026 | Citadel Advisors LLC | 13G/A | 4.3% |
Questions about Aardvark Therapeutics, Inc. (AARD) stock
Who owns the most AARD stock?
The largest reported owner of Aardvark Therapeutics, Inc. (AARD) is Decheng Capital LLC, with 18.0% of the company. In total, 72 funds and institutions reported holding AARD at the end of Q2 2026, together about 44% of the shares. See the largest owners.
Are AARD insiders buying or selling?
In the last 12 months, AARD insiders reported 2 open-market purchases worth $145K and 2 sales worth $395K. The latest trade was on Sep 11, 2026. See every trade.
What is the short interest in AARD?
As of Oct 30, 2026, 1.04M AARD shares were sold short, 4.7% of the shares outstanding, up 87.8% from the report before. At the average daily volume of 2.76M shares, buying them all back would take about 1.0 trading days (days to cover). See the history.
Which famous investors hold AARD?
3 of the 50 well-known investors we track reported AARD in their latest 13F filing, including Ken Griffin, Israel Englander, Steve Cohen. The largest position is worth $5.1M. See all holders.
Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.